Anixa Biosciences Inc

NASDAQ ANIX

Data sourced from

and

Download Data

Anixa Biosciences Inc Debt to Tangible Net Worth Ratio for the quarter ending January 31, 2024

Anixa Biosciences Inc Debt to Tangible Net Worth Ratio is NA for the quarter ending January 31, 2024. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth.

NASDAQ: ANIX

Anixa Biosciences Inc

CEO	Dr. Amit Kumar Ph.D.
IPO Date	Jan. 1, 1987
Location	United States
Headquarters	3150 Almaden Expressway, San Jose, CA, United States, 95118
Employees	4
Sector	Healthcare
Industry	Biotechnology

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key trends